178 related articles for article (PubMed ID: 29194406)
1. Whole Body and CNS Biodistribution of rhHNS in Cynomolgus Monkeys after Intrathecal Lumbar Administration: Treatment Implications for Patients with MPS IIIA.
Chung JK; Pan L; Palmieri K; Youssef AS; McCauley TG
Int J Mol Sci; 2017 Dec; 18(12):. PubMed ID: 29194406
[TBL] [Abstract][Full Text] [Related]
2. A phase 1/2 study of intrathecal heparan-N-sulfatase in patients with mucopolysaccharidosis IIIA.
Jones SA; Breen C; Heap F; Rust S; de Ruijter J; Tump E; Marchal JP; Pan L; Qiu Y; Chung JK; Nair N; Haslett PAJ; Barbier AJ; Wijburg FA
Mol Genet Metab; 2016 Jul; 118(3):198-205. PubMed ID: 27211612
[TBL] [Abstract][Full Text] [Related]
3. Long-term safety and clinical outcomes of intrathecal heparan-N-sulfatase in patients with Sanfilippo syndrome type A.
Wijburg FA; Heap F; Rust S; de Ruijter J; Tump E; Marchal JP; Nestrasil I; Shapiro E; Jones SA; Alexanderian D
Mol Genet Metab; 2021 Dec; 134(4):317-322. PubMed ID: 34600820
[TBL] [Abstract][Full Text] [Related]
4. Intrathecal heparan-N-sulfatase in patients with Sanfilippo syndrome type A: A phase IIb randomized trial.
Wijburg FA; Whitley CB; Muenzer J; Gasperini S; Del Toro M; Muschol N; Cleary M; Sevin C; Shapiro E; Bhargava P; Kerr D; Alexanderian D
Mol Genet Metab; 2019 Feb; 126(2):121-130. PubMed ID: 30528227
[TBL] [Abstract][Full Text] [Related]
5. A multicenter open-label extension study of intrathecal heparan-N-sulfatase in patients with Sanfilippo syndrome type A.
Wijburg FA; Whitley CB; Muenzer J; Gasperini S; Del Toro M; Muschol N; Cleary M; Sevin C; Shapiro E; Alexanderian D
Mol Genet Metab; 2021; 134(1-2):175-181. PubMed ID: 34247932
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and bioavailability of a therapeutic enzyme (idursulfase) in cynomolgus monkeys after intrathecal and intravenous administration.
Xie H; Chung JK; Mascelli MA; McCauley TG
PLoS One; 2015; 10(4):e0122453. PubMed ID: 25836678
[TBL] [Abstract][Full Text] [Related]
7. Enzyme Replacement Therapy for Mucopolysaccharidosis IIID using Recombinant Human α-
Wang F; Moen DR; Sauni C; Kan SH; Li S; Le SQ; Lomenick B; Zhang X; Ekins S; Singamsetty S; Wood J; Dickson PI; Chou TF
Mol Pharm; 2021 Jan; 18(1):214-227. PubMed ID: 33320673
[TBL] [Abstract][Full Text] [Related]
8. Determination of the role of injection site on the efficacy of intra-CSF enzyme replacement therapy in MPS IIIA mice.
Beard H; Luck AJ; Hassiotis S; King B; Trim PJ; Snel MF; Hopwood JJ; Hemsley KM
Mol Genet Metab; 2015 May; 115(1):33-40. PubMed ID: 25795516
[TBL] [Abstract][Full Text] [Related]
9. Biodistribution of Idursulfase Formulated for Intrathecal Use (Idursulfase-IT) in Cynomolgus Monkeys after Intrathecal Lumbar Administration.
Chung JK; Brown E; Crooker B; Palmieri KJ; McCauley TG
PLoS One; 2016; 11(10):e0164765. PubMed ID: 27764180
[TBL] [Abstract][Full Text] [Related]
10. Slow, continuous enzyme replacement via spinal CSF in dogs with the paediatric-onset neurodegenerative disease, MPS IIIA.
King B; Marshall NR; Hassiotis S; Trim PJ; Tucker J; Hattersley K; Snel MF; Jolly RD; Hopwood JJ; Hemsley KM
J Inherit Metab Dis; 2017 May; 40(3):443-453. PubMed ID: 27832416
[TBL] [Abstract][Full Text] [Related]
11. Brain Targeting in MPS-IIIA.
Sorrentino NC; Fraldi A
Pediatr Endocrinol Rev; 2016 Jun; 13 Suppl 1():630-8. PubMed ID: 27491210
[TBL] [Abstract][Full Text] [Related]
12. CNS penetration of intrathecal-lumbar idursulfase in the monkey, dog and mouse: implications for neurological outcomes of lysosomal storage disorder.
Calias P; Papisov M; Pan J; Savioli N; Belov V; Huang Y; Lotterhand J; Alessandrini M; Liu N; Fischman AJ; Powell JL; Heartlein MW
PLoS One; 2012; 7(1):e30341. PubMed ID: 22279584
[TBL] [Abstract][Full Text] [Related]
13. Low-dose, continuous enzyme replacement therapy ameliorates brain pathology in the neurodegenerative lysosomal disorder mucopolysaccharidosis type IIIA.
King B; Hassiotis S; Rozaklis T; Beard H; Trim PJ; Snel MF; Hopwood JJ; Hemsley KM
J Neurochem; 2016 May; 137(3):409-22. PubMed ID: 26762778
[TBL] [Abstract][Full Text] [Related]
14. Safety, pharmacokinetics and CNS distribution of tralesinidase alfa administered via intracerebroventricular infusion to juvenile cynomolgus monkeys.
Pinkstaff J; McCullagh E; Grover A; Melton AC; Cherukuri A; Wait JC; Nguyen A; Butt MT; Trombley JL; Reed RP; Adams EL; Boyd RB; Chandra S; Henshaw J; O'Neill CA; Zanelli E; Kovalchin J
Toxicol Rep; 2023; 10():357-366. PubMed ID: 36923444
[TBL] [Abstract][Full Text] [Related]
15. Caprine mucopolysaccharidosis IIID: a preliminary trial of enzyme replacement therapy.
Downs-Kelly E; Jones MZ; Alroy J; Cavanagh KT; King B; Lucas RE; Baker JC; Kraemer SA; Hopwood JJ
J Mol Neurosci; 2000 Dec; 15(3):251-62. PubMed ID: 11303788
[TBL] [Abstract][Full Text] [Related]
16. Functional correction of CNS lesions in an MPS-IIIA mouse model by intracerebral AAV-mediated delivery of sulfamidase and SUMF1 genes.
Fraldi A; Hemsley K; Crawley A; Lombardi A; Lau A; Sutherland L; Auricchio A; Ballabio A; Hopwood JJ
Hum Mol Genet; 2007 Nov; 16(22):2693-702. PubMed ID: 17725987
[TBL] [Abstract][Full Text] [Related]
17. Intrathecal administration of recombinant human N-acetylgalactosamine 4-sulfatase to a MPS VI patient with pachymeningitis cervicalis.
Muñoz-Rojas MV; Horovitz DD; Jardim LB; Raymundo M; Llerena JC; de Magalhães Tde S; Vieira TA; Costa R; Kakkis E; Giugliani R
Mol Genet Metab; 2010 Apr; 99(4):346-50. PubMed ID: 20036175
[TBL] [Abstract][Full Text] [Related]
18. Effect of cisternal sulfamidase delivery in MPS IIIA Huntaway dogs--a proof of principle study.
Hemsley KM; Norman EJ; Crawley AC; Auclair D; King B; Fuller M; Lang DL; Dean CJ; Jolly RD; Hopwood JJ
Mol Genet Metab; 2009 Dec; 98(4):383-92. PubMed ID: 19699666
[TBL] [Abstract][Full Text] [Related]
19. Intravenous delivery of a chemically modified sulfamidase efficiently reduces heparan sulfate storage and brain pathology in mucopolysaccharidosis IIIA mice.
Gustavsson S; Ohlin Sjöström E; Tjernberg A; Janson J; Westermark U; Andersson T; Makower Å; Arnelöf E; Andersson G; Svartengren J; Ekholm C; Svensson Gelius S
Mol Genet Metab Rep; 2019 Dec; 21():100510. PubMed ID: 31528541
[TBL] [Abstract][Full Text] [Related]
20. Safety evaluation of chronic intrathecal administration of heparan N-sulfatase in juvenile cynomolgus monkeys.
Pfeifer RW; Felice BR; Boyd RB; Butt MT; Ruiz JA; Heartlein MW; Calias P
Drug Deliv Transl Res; 2012 Jun; 2(3):187-200. PubMed ID: 25786866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]